Provided herein are methods for reducing, minimizing, or controlling drug-drug interactions resulting from administration of a first drug that is vadadustat (i.e., {[5-(3- chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1)) and a second drug (for example, a drug comprising a multivalent cation such as calcium, iron, magnesium, lanthanum, aluminum, and the like; a statin drug; sulfasalazine; or furosemide), to a subject.

The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

There are provided, inter alia, methods for treatment of cancer. The methods include means of identifying the NAD biosynthetic pathway on which depend cancer cells in a tumor, in a subject suffering from cancer. The methods further include administering to a subject in need a therapeutically effective amount of an inhibitor of the NMRK1 enzyme pathway to a tumor where the cancer cells are dependent of the NAD salvage pathway, allowing to lower the of dose FK866 administered to the subject. The methods also include administering to a subject in need a therapeutically effective amount of a bacterial inhibitor of NADSYN1 to a tumor where the cancer cells depend on the Preiss Handler pathway.

There are provided, inter alia, methods for treatment of cancer. The methods include means of identifying the NAD biosynthetic pathway on which depend cancer cells in a tumor, in a subject suffering from cancer. The methods further include administering to a subject in need a therapeutically effective amount of an inhibitor of the NMRK1 enzyme pathway to a tumor where the cancer cells are dependent of the NAD salvage pathway, allowing to lower the of dose FK866 administered to the subject. The methods also include administering to a subject in need a therapeutically effective amount of a bacterial inhibitor of NADSYN1 to a tumor where the cancer cells depend on the Preiss Handler pathway.

A pharmaceutical combination, includes an inhibitor of the Wnt/β-catenin signaling pathway and an inhibitor of MACC1. One combination includes an inhibitor of S100A4 as a Wnt-signaling inhibitor, preferably niclosamide, and a statin or MEK1 inhibitor as an inhibitor of MACC1. A pharmaceutical composition can include the combination. The combination or composition can be used in the treatment of a tumor disease, such as a solid tumor, and/or for the treatment and/or prophylaxis of tumor metastasis.

A pharmaceutical combination, includes an inhibitor of the Wnt/β-catenin signaling pathway and an inhibitor of MACC1. One combination includes an inhibitor of S100A4 as a Wnt-signaling inhibitor, preferably niclosamide, and a statin or MEK1 inhibitor as an inhibitor of MACC1. A pharmaceutical composition can include the combination. The combination or composition can be used in the treatment of a tumor disease, such as a solid tumor, and/or for the treatment and/or prophylaxis of tumor metastasis.

Provided herein are compositions and methods for preventing or treating gastrointestinal injury induced by chemotherapy or radiotherapy.

Provided herein are compositions and methods for preventing or treating gastrointestinal injury induced by chemotherapy or radiotherapy.

Provided herein are compositions and methods for preventing or treating gastrointestinal injury induced by chemotherapy or radiotherapy.